Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress, Psychological | 19 | 2023 | 824 | 4.750 |
Why?
|
| Locus Coeruleus | 9 | 2023 | 55 | 3.120 |
Why?
|
| Cardiovascular Diseases | 7 | 2020 | 940 | 2.100 |
Why?
|
| Corticotropin-Releasing Hormone | 10 | 2018 | 79 | 1.920 |
Why?
|
| Depression | 9 | 2022 | 943 | 1.710 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 7 | 2020 | 24 | 1.420 |
Why?
|
| Norepinephrine | 3 | 2019 | 276 | 1.270 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2023 | 2083 | 1.150 |
Why?
|
| Dominance-Subordination | 3 | 2018 | 11 | 1.100 |
Why?
|
| Individuality | 3 | 2016 | 44 | 1.010 |
Why?
|
| Microglia | 2 | 2023 | 143 | 0.960 |
Why?
|
| Inflammation | 6 | 2020 | 1030 | 0.910 |
Why?
|
| Rats | 17 | 2023 | 5300 | 0.890 |
Why?
|
| Rats, Long-Evans | 7 | 2019 | 203 | 0.810 |
Why?
|
| Sex Characteristics | 2 | 2021 | 295 | 0.790 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2020 | 52 | 0.780 |
Why?
|
| Cytokines | 4 | 2021 | 866 | 0.770 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 16 | 0.730 |
Why?
|
| Adaptation, Psychological | 4 | 2019 | 447 | 0.720 |
Why?
|
| Animals | 23 | 2023 | 20881 | 0.690 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2020 | 61 | 0.670 |
Why?
|
| Connexin 43 | 1 | 2019 | 62 | 0.650 |
Why?
|
| Brain | 6 | 2022 | 2176 | 0.650 |
Why?
|
| Behavior, Addictive | 1 | 2022 | 317 | 0.640 |
Why?
|
| Pyrimidines | 4 | 2013 | 178 | 0.610 |
Why?
|
| Social Environment | 2 | 2016 | 182 | 0.600 |
Why?
|
| Stress, Physiological | 2 | 2017 | 215 | 0.590 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 439 | 0.580 |
Why?
|
| Raphe Nuclei | 2 | 2016 | 10 | 0.580 |
Why?
|
| Stilbenes | 1 | 2016 | 57 | 0.540 |
Why?
|
| Depressive Disorder | 2 | 2019 | 621 | 0.540 |
Why?
|
| Cardiovascular System | 1 | 2016 | 85 | 0.520 |
Why?
|
| Dorsal Raphe Nucleus | 1 | 2014 | 2 | 0.500 |
Why?
|
| Antioxidants | 1 | 2016 | 304 | 0.470 |
Why?
|
| Serotonergic Neurons | 1 | 2013 | 1 | 0.440 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2013 | 12 | 0.440 |
Why?
|
| Adaptation, Biological | 1 | 2013 | 14 | 0.440 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 244 | 0.430 |
Why?
|
| Urodynamics | 1 | 2013 | 43 | 0.430 |
Why?
|
| Male | 20 | 2023 | 37321 | 0.430 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 1242 | 0.420 |
Why?
|
| Anhedonia | 3 | 2017 | 15 | 0.400 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2019 | 1506 | 0.400 |
Why?
|
| Urinary Bladder | 2 | 2010 | 108 | 0.400 |
Why?
|
| Heart Rate | 4 | 2018 | 568 | 0.380 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2009 | 26 | 0.350 |
Why?
|
| Cardiotonic Agents | 1 | 2009 | 71 | 0.340 |
Why?
|
| Urination Disorders | 1 | 2009 | 20 | 0.330 |
Why?
|
| Central Amygdaloid Nucleus | 2 | 2019 | 16 | 0.320 |
Why?
|
| Vagus Nerve | 3 | 2020 | 90 | 0.310 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 2550 | 0.310 |
Why?
|
| Autonomic Nervous System | 1 | 2007 | 31 | 0.300 |
Why?
|
| Anxiety | 2 | 2022 | 422 | 0.280 |
Why?
|
| Vagus Nerve Diseases | 1 | 2006 | 1 | 0.280 |
Why?
|
| Hippocampus | 2 | 2021 | 471 | 0.270 |
Why?
|
| Bradycardia | 1 | 2006 | 45 | 0.270 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 75 | 0.260 |
Why?
|
| Comorbidity | 2 | 2022 | 1426 | 0.260 |
Why?
|
| Social Behavior | 3 | 2017 | 164 | 0.250 |
Why?
|
| Cocaine | 1 | 2009 | 555 | 0.240 |
Why?
|
| Cocaine-Related Disorders | 1 | 2009 | 504 | 0.240 |
Why?
|
| Telemetry | 2 | 2017 | 23 | 0.230 |
Why?
|
| Antidepressive Agents | 2 | 2020 | 216 | 0.220 |
Why?
|
| Humans | 10 | 2022 | 68618 | 0.210 |
Why?
|
| Female | 7 | 2023 | 38074 | 0.200 |
Why?
|
| Behavior, Animal | 2 | 2017 | 470 | 0.190 |
Why?
|
| Peptide Fragments | 3 | 2020 | 483 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 455 | 0.180 |
Why?
|
| Septal Nuclei | 1 | 2020 | 31 | 0.180 |
Why?
|
| Baroreflex | 1 | 2020 | 20 | 0.180 |
Why?
|
| Blood Pressure | 3 | 2020 | 1451 | 0.180 |
Why?
|
| Ovary | 1 | 2020 | 99 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.170 |
Why?
|
| Benzylamines | 1 | 2019 | 28 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2010 | 150 | 0.160 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.160 |
Why?
|
| Peer Review | 1 | 2018 | 16 | 0.160 |
Why?
|
| Physiology | 1 | 2018 | 12 | 0.160 |
Why?
|
| Biostatistics | 1 | 2018 | 43 | 0.160 |
Why?
|
| Ovariectomy | 1 | 2018 | 49 | 0.150 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.150 |
Why?
|
| Action Potentials | 3 | 2015 | 223 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2018 | 47 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 88 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2010 | 106 | 0.150 |
Why?
|
| Corticosterone | 1 | 2017 | 51 | 0.140 |
Why?
|
| Sucrose | 1 | 2017 | 58 | 0.140 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2017 | 59 | 0.140 |
Why?
|
| Mitochondria | 1 | 2022 | 643 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 381 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 158 | 0.130 |
Why?
|
| Spleen | 1 | 2016 | 301 | 0.130 |
Why?
|
| Aging | 1 | 2021 | 911 | 0.130 |
Why?
|
| Pyrroles | 2 | 2006 | 83 | 0.120 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2014 | 18 | 0.120 |
Why?
|
| Adrenergic Neurons | 1 | 2013 | 7 | 0.110 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2013 | 27 | 0.110 |
Why?
|
| Dependovirus | 1 | 2013 | 34 | 0.110 |
Why?
|
| Biotin | 1 | 2013 | 28 | 0.110 |
Why?
|
| Pons | 1 | 2013 | 35 | 0.110 |
Why?
|
| beta-Arrestins | 1 | 2013 | 80 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 70 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 742 | 0.110 |
Why?
|
| Serotonin | 1 | 2013 | 144 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1745 | 0.100 |
Why?
|
| Reaction Time | 1 | 2013 | 170 | 0.100 |
Why?
|
| Arrestins | 1 | 2013 | 92 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2013 | 312 | 0.100 |
Why?
|
| Restraint, Physical | 2 | 2010 | 59 | 0.100 |
Why?
|
| RNA | 1 | 2013 | 171 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 770 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2012 | 45 | 0.100 |
Why?
|
| Desipramine | 1 | 2012 | 47 | 0.100 |
Why?
|
| Pituitary-Adrenal System | 2 | 2010 | 138 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 434 | 0.100 |
Why?
|
| Mice | 2 | 2021 | 8474 | 0.090 |
Why?
|
| Arginine Vasopressin | 1 | 2010 | 16 | 0.090 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2010 | 15 | 0.090 |
Why?
|
| Pituitary Gland | 1 | 2010 | 29 | 0.090 |
Why?
|
| Heart Failure | 1 | 2019 | 1180 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 201 | 0.090 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 640 | 0.090 |
Why?
|
| Neurons | 1 | 2015 | 881 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 114 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 72 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 219 | 0.080 |
Why?
|
| Swimming | 2 | 2006 | 38 | 0.080 |
Why?
|
| Hypotension | 1 | 2009 | 74 | 0.080 |
Why?
|
| Brain Stem | 1 | 2009 | 46 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2009 | 89 | 0.080 |
Why?
|
| Urinary Retention | 1 | 2009 | 20 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2013 | 298 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 554 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2007 | 40 | 0.070 |
Why?
|
| Seizures | 1 | 2009 | 279 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2007 | 107 | 0.070 |
Why?
|
| Mifepristone | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cholinergic Antagonists | 1 | 2006 | 17 | 0.070 |
Why?
|
| Psychomotor Agitation | 1 | 2006 | 63 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 236 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1664 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2006 | 93 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 132 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 141 | 0.060 |
Why?
|
| Triazoles | 1 | 2005 | 43 | 0.060 |
Why?
|
| Time Factors | 1 | 2010 | 4655 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 532 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 371 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 682 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.040 |
Why?
|
| Brain Waves | 1 | 2015 | 30 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2015 | 47 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 2791 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2015 | 206 | 0.030 |
Why?
|
| Heart | 1 | 2018 | 850 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 324 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 772 | 0.030 |
Why?
|
| Naloxone | 1 | 2013 | 56 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 184 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 26 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 435 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 14862 | 0.010 |
Why?
|
| Middle Aged | 1 | 2019 | 21147 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 21403 | 0.010 |
Why?
|